908 Devices Inc. (MASS) Stock Price & Analysis
908 Devices Inc. (MASS) closed at USD 11.35 on Thursday, October 22, 2026, down 3.81% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 11.8; the Oct 22, 2026 session ranged USD 11.15–11.78 on volume of 256,516 shares. Market capitalization is $469.14M, with a 52-week range of USD 5.03–13.35 (NGM). Source: Nexqual, retrieved October 23, 2026 at 09:24 UTC.
Also available as compact Markdown for AI agents: nexqual.com/MASS.md
Key facts (MASS)
- Last four reported quarters (through Jun 30, 2026): revenue $60.8M, net income -$34.7M (-57.0% margin), free cash flow $615K (SEC filings).
- 1 of 80 tracked superinvestors hold MASS (13F, Q2 2026): 0 new, 1 added, 0 reduced, 0 unchanged.
- Analysts: Buy (mean 2.00 on a 1–5 scale) (6 analysts), mean target USD 13.38 (range 12–14).
- Total return with dividends: 1Y +35.1% vs S&P 500 +14.9%; 5Y -67.3% vs S&P 500 +80.3%.
- Next earnings: 2026-11-10, EPS estimate USD -0.11, revenue estimate $18.3M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (MASS)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $42.2M | $46.9M | $50.2M | $47.7M | $56.2M | $60.8M |
| Gross profit | $23.2M | $26.0M | $25.3M | $24.5M | $28.4M | — |
| Operating income | -$22.1M | -$35.4M | -$42.8M | -$57.4M | -$39.4M | -$38.9M |
| Net income | -$22.2M | -$33.6M | -$36.4M | -$72.2M | $19.5M | -$34.7M |
| EPS (diluted) | -$0.79 | -$1.07 | -$1.13 | -$2.12 | $0.54 | — |
| Free cash flow | -$29.8M | -$23.0M | -$27.1M | -$30.8M | -$24.6M | $615K |
| Gross margin | 55.0% | 55.5% | 50.4% | 51.3% | 50.6% | — |
| Operating margin | -52.3% | -75.5% | -85.1% | -120.2% | -70.1% | -64.0% |
| Net margin | -52.5% | -71.6% | -72.5% | -151.2% | 34.7% | -57.0% |
| Revenue growth | +56.9% | +11.0% | +7.2% | -4.9% | +17.7% | — |
| Cash + short-term investments | $224M | $188M | $146M | $69.6M | $113M | — |
| Total debt | $15.0M | $15.0M | — | — | — | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (MASS)
P/S 7.7x · P/FCF 762.8x · P/B 3.7x · FCF yield 0.13% · Earnings yield -7.39%
P/E at fiscal year-ends: Dec 2025 9.7x.
Superinvestors (SEC 13F-HR, Q2 2026) (MASS)
1 of 80 tracked investors hold MASS. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| First Eagle Investment | First Eagle Investment Management | 0.01% | $8.1M | Added +15.7% |
Analysts (MASS)
Consensus Buy (mean 2.00 on a 1–5 scale), 6 analysts; mean target USD 13.38 (low 12, high 14).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-10 | Canaccord Genuity | Initiated | Buy | $13.5 |
| 2026-08-12 | Stifel | Target raised | Buy | $10 → $12 |
| 2026-08-12 | Roth Capital | Target raised | Buy | $11 → $13 |
| 2026-07-29 | Roth Capital | Initiated | Buy | $11 |
Total return (dividends reinvested) (MASS)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +35.1% | -67.3% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +35.3% | -20.0% |
| Volatility (annualized) | 60.6% | 81.3% |
| Max drawdown | -40.2% (Oct 2025→Jan 2026) | -94.6% (Nov 2021→Dec 2024) |
MASS revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Product | $13.0M | 80.7% | +35.5% |
| Device Sales | $11.0M | 68.6% | +33.1% |
| Recurring | $4.9M | 30.8% | +4.5% |
| Service | $3.1M | 19.3% | -10.4% |
| Contract | $104,000 | 0.6% | +420.0% |
| Total revenue | $16.1M | 100% | — |
MASS revenue by region (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| United States | $11.8M | 73.7% | +8.4% |
| EMEA | $2.3M | 14.3% | +68.5% |
| Asia Pacific | $1.5M | 9.6% | +130.4% |
| Americas Other | $383,000 | 2.4% | +463.2% |
| Total revenue | $16.1M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
MASS suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | REPLIGEN CORP (RGEN) | “On the Closing Date, the company entered into a Supply Agreement with Repligen under which the Company will supply certain components to Repligen related to the Rebel product offering.” |
| Competitor | Thermo Fisher (TMO) | “We have a range of competitors extending from small, privately held companies with single-point solutions to large, publicly-held corporations, including those with a portfolio of Mass Spec and/or spectroscopy products, such as Agilent, Bruker, Danaher, Inficon, Teledyne, Rigaku, and Thermo Fisher Scientific.” |
Quoted from the company's 10-K filed Mar 9, 2026.
MASS customer concentration
In the period ended Jun 30, 2026, a single direct customer accounted for 13% of revenue, per the company's 10-Q filed Aug 11, 2026. The company does not name it.
MASS company outlook (results filed Aug 11, 2026)
- “Revenue increased 23% compared to prior year Updated full year 2026 outlook reflects 21% to 25% year-over-year growth BURLINGTON, Mass. – August 11, 2026 – 908 Devices Inc.”
Quoted word-for-word from the SEC 8-K results press release.
MASS analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.10 | $-0.08 | +31.3% | $18.3M | 4 |
| Next quarter (ends Dec 2026) | $-0.06 | $-0.03 | +88.9% | $21.3M | 3 |
| Current fiscal year (ends Dec 2026) | $-0.48 | $-0.36 | +32.1% | $69.1M | 3 |
| Next fiscal year (ends Dec 2027) | $-0.31 | $-0.29 | +7.3% | $82.5M | 4 |
Key Statistics (as of October 23, 2026 at 09:24 UTC)
| Price | USD 11.35 |
|---|---|
| Change | ▼ 3.81% (down) |
| Previous Close | USD 11.8 |
| Open | USD 11.58 |
| Day Range | USD 11.15 – 11.78 |
| 52-Week Range | USD 5.03 – 13.35 |
| Volume | 256,516 shares |
| Market Cap | $469.14M |
| Exchange | NGM |
Technical Analysis (MASS)
Nexqual's technical model rates MASS "BUY" based on 4 bullish and 2 bearish signals across 127 daily candles, as of October 23, 2026 at 09:24 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 49.26 (neutral) |
| vs SMA50 | Above (USD 10.99) |
| MACD | 0.18 (positive) |
Analyst Ratings (MASS)
Wall Street analysts rate MASS "Buy" based on 6 analysts, with a mean price target of USD 13.38 (range USD 12–14), per Nexqual as of October 23, 2026 at 09:24 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 13.38 |
| High Target | USD 14 |
| Low Target | USD 12 |
| Buy / Hold / Sell | 6 / 0 / 0 |
Earnings (MASS)
| Next Earnings Date | 2026-11-10 |
|---|---|
| EPS Estimate | USD -0.11 |
| Revenue Estimate | $18.31M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.06 vs est -0.14 ▲ beat |
| 2026-03-31 | USD -0.07 vs est -0.14 ▲ beat |
| 2025-12-31 | USD 0.02 vs est -0.06 ▲ beat |
| 2025-09-30 | USD -0.04 vs est -0.12 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:24 UTC.
Financials & Fundamentals (MASS)
| Total Revenue | $60.84M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +23.30% |
| Gross Margin | +52.65% |
| Operating Margin | -39.61% |
| Profit Margin | -56.96% |
| ROE | -24.95% |
| Debt / Equity | 0.03 |
| Current Ratio | 2.67 |
| Total Cash | $101.53M |
| Total Debt | $4.30M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $615,000 (1.0% of revenue) |
Source: Nexqual, October 23, 2026 at 09:24 UTC.
Financial Health Score (MASS)
Nexqual rates 908 Devices Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 09:24 UTC.
| Growth | Weak — Revenue -6% YoY (annual), declining |
|---|---|
| Profitability | Mixed — Gross margin 53%, operating -40% (last 12 months) |
| Balance Sheet | Strong — $102M cash vs $4M debt, net cash position |
| Cash Flow | Mixed — FCF $615K (last 4 quarters to Jun 2026, SEC), slim 1.0% margin |
| Efficiency | Critical — ROE -25%, ROA -6.8% |
Ownership (MASS)
| Insider Ownership | +7.45% |
|---|---|
| Institutional Ownership | +83.80% |
| Shares Outstanding | 41.33M |
| Float | 28.07M |
| Short % of Float | +12.85% |
Source: Nexqual, October 23, 2026 at 09:24 UTC.
Leadership (MASS)
908 Devices Inc. is led by Kevin J. Knopp, Co-Founder, CEO, President & Director, per Nexqual as of October 23, 2026 at 09:24 UTC.
| Co-Founder, CEO, President & Director | Kevin J. Knopp |
|---|---|
| Co-Founder, Board Advisor & Director | Christopher David Brown |
| CFO & Treasurer | Joseph H. Griffith |
| Senior Vice President of Sales and Product Marketing | John Kenneweg |
| Senior Vice President of Products and Production | Kevin McCallion |
Major Backers & Investors (MASS)
Notable institutional backers of 908 Devices Inc. include First Light Asset Management, LLC, AWM Investment Company, Inc., ARK Invest, according to Nexqual as of October 23, 2026 at 09:24 UTC.
Active Investors
| Investor | Stake |
|---|---|
| First Light Asset Management, LLC | 15.2% |
| AWM Investment Company, Inc. | 11.81% |
| ARK Invest | 4.91% |
| Needham Investment Management, L.L.C. | 4.4% |
| Needham Funds Inc-Needham Aggressive Growth Fund | 3.99% |
| American Century ETF Trust-Avantis U.S. Small Cap Value ETF | 2.27% |
| First Eagle Investment Management, LLC | 2.25% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 4.7% |
| Vanguard Group | 3.12% |
| Geode Capital | 1.84% |
Source: Nexqual, October 23, 2026 at 09:24 UTC.
From 908 Devices Inc.'s Latest SEC 10-K Filing (filed 2026-03-09)
Key Strengths & Strategy (as disclosed to the SEC)
- A key component of our technology is our proprietary microscale ion trap, which we estimate is 1,000 times smaller than those in conventional laboratory Mass Spec instruments.
- The MX908's machine-learning software, enabled by our proprietary technology platform, serves as a critical element of the device.
- Since the launch of our first device in 2014, we have sold more than 3,700 handheld devices to over 700 customers, including numerous domestic and foreign government agencies.
- Our proprietary Mass Spec platform relies on extreme miniaturization of the core of Mass Spec -- the ion trap and its vacuum system.
Legal & Regulatory Risks (Item 1A, quoted)
- We are party to royalty-bearing license agreements and we may need to obtain additional licenses from others to advance our research, development and commercialization activities.
- Changes in patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.
- Changes in either the patent laws or in interpretations of patent laws in the United States or other countries or regions may diminish the value of our intellectual property. We cannot predict the breadth of claims that may be allowed or enforced in our patents or in third party patents. We may not develop additional proprietary products, methods and technologies that are patentable.
- Our ability to compete and the success of our business could be jeopardized if we are unable to protect our intellectual property adequately.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| NVCR | NovoCure Limited | USD 15.1 | ▼ 3.14% |
| ESTA | Establishment Labs Holdings Inc | USD 63.52 | ▲ 1.99% |
| BFLY | Butterfly Network, Inc. | USD 6.81 | ▼ 4.08% |
| INSP | Inspire Medical Systems, Inc. | USD 72.66 | ▲ 2.24% |
| AXGN | AxoGen, Inc. | USD 36.68 | ▲ 0.55% |
| ALMR | Alamar Biosciences, Inc. | USD 29.72 | ▼ 5.5% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:24 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt